Triple Progress Analysis - Melanoma, Colorectal & Lung Cancer - Biologics Market Research

Triple Progress Analysis - Melanoma, Colorectal & Lung Cancer

Published Date: March 2006
Published By: BioSeeker Group AB
Order Code: R474-192
Price: $4,554.00 Hard Copy Mail Delivery
$4,554.00 PDF E-mail From Publisher
Note: If you don't see the format or license type you require, please contact a customer service representative for assistance.
DESCRIPTION

Introduction
Novel therapeutic strategies are emerging in cancer treatment. Melanoma, colorectal and lung cancer are all cancer types subjected to a large potion of innovative drug candidates. In this 400 page report BioSeeker Group has compiled and analyzed information concerning drug development and competitive situation on three major cancer indications. The report not only provides a framework for current progress in the treatment for these cancer types but as well a careful identification and evaluation of drug candidates. BioSeeker Group has identified 155 drugs under development; many of them in late developmental stage. The activities of 170 companies are reported.
Melanoma drug development has and will continue to have a strong focus on target therapy such as vaccines, monoclonal antibodies, dendritic cells, and gene therapy. In recent years, immunologic strategies including tumor vaccine and adjuvant therapy with interferon-alfa have been attempted to improve survival of patients with more advanced malignant melanoma. Another emerging strategy in anticancer therapy is the targeting of chemotherapy resistance by overcoming the antiapoptosis mechanisms of cancer cells. An example of this approach is the novel antisense oligonucleotide Genasense that targets the antiapoptotic gene bcl-2. Recently, Genta initiated a European regulatory submission for Genasense plus chemotherapy for patients with advanced melanoma by sending a letter of intent to EMEA for Marketing Authorization Application.
Colorectal cancer is the second most common cause of cancer death in much of the developed world. Cancer-related mortality is slowly decreasing as a result of better detection and significant advances in the treatment of advanced colorectal cancer over the past 5 years. This is most prominent due to the introduction of three novel cytotoxic agents - Xeloda, Camptosar, and Eloxatin - and the recent approval of the two antibodies - Avastin and Erbitux. Interestingly, an army of novel agents and targets are currently in Phase II clinical trials, and their contributions and impact on future therapy in colorectal cancer remains to be seen.
Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for NSCLC: cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced NSCLC. However, despite their contributions, science has reached a therapeutic plateau. Both Avastin and Efaproxyn have generated exciting data. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 21 late stage drug candidates are described and analysed. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost effective way. By gathering information around most drugs under development for lung cancer and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis? Taxotere (docetaxel), Bristol-Myers Squibb?s Paraplatin (carboplatin) and Eli Lilly?s Gemzar (gemcitabine).
This report covers the latest on:
Disease overview, including incidence, unmet needs, risk factors, screening and diagnosis.
Analysis of current treatments, key therapeutic strategies and combination therapies.
Progress analysis on pipeline products, including emerging and hot pre-clinical data, discontinued projects, clinical trial information, commercial potential and limiting factors.
Competitive landscape analysis
Scope of this report:
Thorough examination of status and impact on novel drugs in development
Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
Case studies on major drugs on market
Competitive landscape assessment, companies in the field and high lightening major competitors
Key reasons to read this report:
Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for novel therapeutics and the results of clinical trials to date.
Novel targets and agents are discussed and organized
Gain insight into the current challenges and commercial opportunities